Effect of acetylcysteine effervescent tablets combined with beclomethasone suspension on immune function, erythrocyte sedimentation rate, and procalcitonin levels in patients with chronic obstructive pulmonary disease
10.3760/cma.j.cn341190-20230908-00172
- VernacularTitle:乙酰半胱氨酸泡腾片联合倍氯米松对COPD患者免疫功能及ESR、PCT水平的影响
- Author:
Zhen BEI
1
;
Junpei WU
Author Information
1. 义乌市中心医院呼吸内科，义乌 322000
- Keywords:
Pulmonary disease, chronic obstructive;
Blood sedimentation;
CD4-positive T-lymphocytes;
CD8-positive T-lymphocytes;
Acetylcysteine;
Beclomethasone;
Treatme
- From:
Chinese Journal of Primary Medicine and Pharmacy
2024;31(7):982-987
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of acetylcysteine effervescent tablets combined with beclomethasone suspension on immune function, erythrocyte sedimentation rate (ESR), and procalcitonin (PCT) levels in patients with chronic obstructive pulmonary disease (COPD).Methods:The clinical data of 102 patients with COPD admitted to Yiwu Central Hospital from January 2022 to June 2023 were retrospectively analyzed. These patients were divided into Group A ( n = 51) and Group B ( n = 51) based on different treatment methods. Group A received symptomatic treatments and beclomethasone suspension, while Group B received the same treatment as Group A plus acetylcysteine effervescent tablets. The clinical efficacy, exercise tolerance, clinical symptoms, quality of life, immune function, and serum ESR and PCT levels were compared between Groups A and B. Results:The total response rate in Group B was 96.08% (49/51), which was significantly higher than that in Group A [82.35% (42/51), χ2 = 5.14, P < 0.05]. After treatment, Group A showed significantly longer distance in the 6-minute walk test (6MWT) and higher levels of CD 3+, CD 4+, and CD 4+/CD 8+ ratio [(317.19 ± 46.70) m, (54.53 ± 7.98)%, (34.76 ± 4.23)%, (1.20 ± 0.28)] compared with before treatment [(266.49 ± 43.01) m, (49.38 ± 8.27)%, (28.75 ± 3.33)%, (0.85 ± 0.21)] ( t6MWT = 5.70, tCD3+= 3.20, tCD4+=7.97, tCD4+/CD8+ = 7.14, all P < 0.001). Group B exhibited significantly longer distance in the 6MWT as well as higher levels of CD 3+, CD 4+, and CD 4+/CD 8+ ratio after treatment [(328.19 ± 41.48) m, (60.02 ± 5.17)%, (36.89 ± 5.59)%, (1.37 ± 0.27)] compared with before treatment [(265.69 ± 49.60) m, (44.33 ± 7.34)%, (28.59 ± 4.35)%, (0.83 ± 0.12)] ( t6MWT = 6.90, tCD3+ = 12.48, tCD4+ = 8.36, tCD4+/CD8+= 13.05, all P < 0.001). After treatment, the distance in 6MWT and the levels of CD 3+, CD 4+, and CD 4+/CD 8+ in Group B were significantly longer or higher compared with Group A ( t6MWT = 3.35, tCD3+ = 10.94, tCD4+ = 5.83, tCD4+/CD8+ = 8.42, all P < 0.05). After treatment, Modified British Medical Research Council Questionnaire (mMRC) score, CAT score, CD 8+ , ESR, and PCT in group A [(1.30 ± 1.04) points, (14.37 ± 4.58) points, (30.61 ± 8.32)%, (24.28 ± 4.88) mm/h, (0.44 ± 0.16) μg/L] were significantly decreased compared with before treatment [(2.53 ± 0.85) points, (20.10 ± 6.34) points, (35.90 ± 9.71)%, (33.26 ± 6.28) mm/h, (0.72 ± 0.16) μg/L, tmMRC = 6.54, tCAT = 5.23, tCD8+ = 4.21, tESR = 8.06, tPCT = 8.83, all P < 0.05). After treatment, mMRC score, CAT score, CD 8+, ESR, and PCT in group B [(1.09 ± 0.90) points, (13.58 ± 3.59) points, (27.63 ± 5.24)%, (23.16 ± 6.71) mm/h, (0.34 ± 0.14) μg/L] were significantly decreased compared with before treatment [(2.47 ± 0.93) points, (19.93 ± 4.60) points, (34.93 ± 5.52)%, (33.25 ± 77.59) mm/h, (0.72 ± 0.12), tmMRC = 7.61, tCAT = 7.77, tCD8+ = 6.85, tESR = 7.11, tPCT = 14.71, all P < 0.05). After treatment, mMRC score, CAT score, CD 8+, ESR, and PCT in group B were significantly lower compared with group A ( tmMRC = 2.87, tCAT = 2.57, tCD8+= 5.74, tESR = 2.57, tPCT = 8.77, all P < 0.05). Conclusion:The combination of acetylcysteine effervescent tablets and beclomethasone demonstrates obvious clinical efficacy in the treatment of COPD patients. The combined therapy effectively improves patients' exercise endurance, clinical symptoms, quality of life, and immune function.
